MX2018010288A - Transposon system and methods of use. - Google Patents
Transposon system and methods of use.Info
- Publication number
- MX2018010288A MX2018010288A MX2018010288A MX2018010288A MX2018010288A MX 2018010288 A MX2018010288 A MX 2018010288A MX 2018010288 A MX2018010288 A MX 2018010288A MX 2018010288 A MX2018010288 A MX 2018010288A MX 2018010288 A MX2018010288 A MX 2018010288A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- immune cell
- transposon system
- sequence encoding
- dna sequence
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 2
- 210000002865 immune cell Anatomy 0.000 abstract 2
- 102000008579 Transposases Human genes 0.000 abstract 1
- 108010020764 Transposases Proteins 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 238000012239 gene modification Methods 0.000 abstract 1
- 230000005017 genetic modification Effects 0.000 abstract 1
- 235000013617 genetically modified food Nutrition 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/90—Vectors containing a transposable element
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
Disclosed are methods for the ex-vivo genetic modification of an immune cell comprising delivering to the immune cell, (a) a nucleic acid or amino acid sequence comprising a sequence encoding a transposase enzyme and (b) a recombinant and non-naturally occurring DNA sequence comprising a DNA sequence encoding a transposon.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662300387P | 2016-02-26 | 2016-02-26 | |
| PCT/US2017/019531 WO2017147538A1 (en) | 2016-02-26 | 2017-02-24 | Transposon system and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018010288A true MX2018010288A (en) | 2019-06-06 |
Family
ID=58314517
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018010288A MX2018010288A (en) | 2016-02-26 | 2017-02-24 | Transposon system and methods of use. |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP3420090A1 (en) |
| JP (1) | JP2019506177A (en) |
| KR (1) | KR20180131545A (en) |
| CN (1) | CN109312361A (en) |
| AU (1) | AU2017224111A1 (en) |
| BR (1) | BR112018067536A2 (en) |
| CA (1) | CA3015642A1 (en) |
| IL (1) | IL261343A (en) |
| MX (1) | MX2018010288A (en) |
| RU (1) | RU2018133691A (en) |
| SG (1) | SG11201807134RA (en) |
| WO (1) | WO2017147538A1 (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102546839B1 (en) | 2016-08-03 | 2023-06-23 | 워싱턴 유니버시티 | Gene editing of CAR-T cells for the treatment of T-cell malignancies using chimeric antigen receptors |
| US20190119636A1 (en) * | 2017-10-23 | 2019-04-25 | Poseida Therapeutics, Inc. | Modified stem cell memory t cells, methods of making and methods of using same |
| EP3555273B1 (en) | 2016-12-16 | 2024-05-22 | B-Mogen Biotechnologies, Inc. | ENHANCED hAT FAMILY TRANSPOSON-MEDIATED GENE TRANSFER AND ASSOCIATED COMPOSITIONS, SYSTEMS, AND METHODS |
| US11278570B2 (en) | 2016-12-16 | 2022-03-22 | B-Mogen Biotechnologies, Inc. | Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods |
| CN108728477B (en) * | 2017-04-24 | 2022-02-22 | 华东理工大学 | An efficient transposition mutation system and construction method |
| US20210115453A1 (en) * | 2017-08-31 | 2021-04-22 | Poseida Therapeutics, Inc. | Transposon system and methods of use |
| AU2018329741B2 (en) * | 2017-09-08 | 2025-02-20 | Poseida Therapeutics, Inc. | Compositions and methods for chimeric ligand receptor (CLR)-mediated conditional gene expression |
| US10329543B2 (en) | 2017-10-23 | 2019-06-25 | Poseida Therapeutics, Inc. | Modified stem cell memory T cells, methods of making and methods of using same |
| CA3104288A1 (en) | 2018-06-21 | 2019-12-26 | B-Mogen Biotechnologies, Inc. | Enhanced hat family transposon-mediated gene transfer and associated compositions, systems, and methods |
| US20220170044A1 (en) * | 2019-02-08 | 2022-06-02 | Dna Twopointo, Inc. | Transposon-based modifications of immune cells |
| CN111926041B (en) * | 2020-10-16 | 2020-12-25 | 广州吉妮欧生物科技有限公司 | SARS-CoV-2 pseudovirus mouse internal packaging system and its preparation method |
| CN114246986B (en) * | 2021-12-29 | 2022-08-23 | 中国人民解放军陆军军医大学 | Cardiovascular implant based on in-situ immune response regulation and control and preparation method thereof |
| CN118185901B (en) * | 2022-12-12 | 2025-03-21 | 北京精缮生物科技有限责任公司 | A PBase protein, fusion protein, nucleic acid and gene integration system and application |
| CN116590341A (en) * | 2023-07-13 | 2023-08-15 | 山东维真生物科技有限公司 | adenovirus-PiggyBac system and preparation method and application thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| AU2008271523B2 (en) | 2007-07-04 | 2015-09-10 | Max-Delbruck-Centrum Fur Molekulare Medizin | Hyperactive variants of the transposase protein of the transposon system Sleeping Beauty |
| SG174155A1 (en) * | 2009-02-25 | 2011-10-28 | Univ Johns Hopkins | Piggybac transposon variants and methods of use |
| EP2401367B1 (en) * | 2009-02-26 | 2016-11-30 | Transposagen Biopharmaceuticals, Inc. | Hyperactive piggybac transposases |
| US20130045491A1 (en) * | 2011-07-19 | 2013-02-21 | Derya Unutmaz | Methods for activating t cells |
| US20150322439A1 (en) * | 2012-11-19 | 2015-11-12 | Nature Technology Corporation | Replicative minicircle vectors with improved expression |
-
2017
- 2017-02-24 EP EP17711046.7A patent/EP3420090A1/en not_active Withdrawn
- 2017-02-24 WO PCT/US2017/019531 patent/WO2017147538A1/en active Application Filing
- 2017-02-24 RU RU2018133691A patent/RU2018133691A/en not_active Application Discontinuation
- 2017-02-24 CN CN201780025816.1A patent/CN109312361A/en active Pending
- 2017-02-24 KR KR1020187027345A patent/KR20180131545A/en not_active Withdrawn
- 2017-02-24 SG SG11201807134RA patent/SG11201807134RA/en unknown
- 2017-02-24 AU AU2017224111A patent/AU2017224111A1/en not_active Abandoned
- 2017-02-24 BR BR112018067536A patent/BR112018067536A2/en not_active IP Right Cessation
- 2017-02-24 MX MX2018010288A patent/MX2018010288A/en unknown
- 2017-02-24 CA CA3015642A patent/CA3015642A1/en not_active Abandoned
- 2017-02-24 JP JP2018544891A patent/JP2019506177A/en active Pending
-
2018
- 2018-08-23 IL IL261343A patent/IL261343A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019506177A (en) | 2019-03-07 |
| AU2017224111A1 (en) | 2018-09-13 |
| RU2018133691A (en) | 2020-03-26 |
| CN109312361A (en) | 2019-02-05 |
| WO2017147538A1 (en) | 2017-08-31 |
| SG11201807134RA (en) | 2018-09-27 |
| EP3420090A1 (en) | 2019-01-02 |
| KR20180131545A (en) | 2018-12-10 |
| CA3015642A1 (en) | 2017-08-31 |
| BR112018067536A2 (en) | 2019-02-05 |
| IL261343A (en) | 2018-10-31 |
| RU2018133691A3 (en) | 2020-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018010288A (en) | Transposon system and methods of use. | |
| PH12019501413A1 (en) | T-cell modulatory multimeric polypeptides and method of use thereof | |
| WO2016046234A3 (en) | Recombinant phe-free proteins for use in the treatment of phenylketonuria | |
| EP3950941A3 (en) | Dnase polypeptide variants | |
| PH12018502645A1 (en) | Optimized mini-dystrophin genes and expression cassettes and their use | |
| WO2015191693A3 (en) | Method for gene editing | |
| PH12019501130A1 (en) | Viral delivery of neoantigens | |
| MX2017014125A (en) | Alpha-amylase variants and polynucleotides encoding same. | |
| GB2569733A (en) | RNA-guided nucleic acid modifying enzymes and methods of use thereof | |
| MX2024007924A (en) | Multiplexed genome editing. | |
| EP4219702A3 (en) | Enzyme variants and polynucleotides encoding the same | |
| WO2014202616A3 (en) | Rasamsonia gene and use thereof | |
| WO2015157579A3 (en) | Enhanced nucleic acid constructs for eukaryotic gene expression | |
| WO2015155686A3 (en) | Methods and compositions for rna-directed repression of transcription using crispr-associated genes | |
| EP3741848A3 (en) | Protease variants and polynucleotides encoding same | |
| MX2022003908A (en) | Enzymes and applications thereof. | |
| AU2016262093A8 (en) | Enhancing endonuclease based gene editing in primary cells | |
| MX2015017110A (en) | Targeted integration. | |
| MX2017003847A (en) | Protease-activatable bispecific proteins. | |
| WO2017062668A3 (en) | Dna vectors, transposons and transposases for eukaryotic genome modification | |
| NZ742068A (en) | Transposon system, kit comprising the same, and uses thereof | |
| EP3760713A3 (en) | Lipase variants and polynucleotides encoding same | |
| EP4357453A3 (en) | Lipase variants, polynucleotides encoding same and the use thereof | |
| EP3964575A3 (en) | Alpha-amylase variants and polynucleotides encoding same | |
| MX382218B (en) | LIPASE VARIANTS AND THE POLYNUCLEOTIDES THAT ENCODE THEM. |